What is HC Wainwright’s Estimate for CADL Q4 Earnings?

Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report) – HC Wainwright issued their Q4 2027 earnings estimates for shares of Candel Therapeutics in a research note issued on Friday, November 13th. HC Wainwright analyst A. Maldonado anticipates that the company will earn ($0.34) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.29) per share.

Candel Therapeutics (NASDAQ:CADL – Get Free Report) last announced its quarterly earnings data on Friday, November 13th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.06.

A number of other research firms also recently weighed in on CADL. Canaccord Genuity Group cut their price target on shares of Candel Therapeutics from $25.00 to $13.00 and set a “buy” rating on the stock in a research note on Friday. Citigroup decreased their price target on shares of Candel Therapeutics from $26.00 to $20.00 and set a “buy” rating on the stock in a report on Monday. Bank of America raised shares of Candel Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $12.00 to $18.00 in a research note on Monday, September 21st. Zacks Research downgraded Candel Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. Finally, Stifel Nicolaus cut their target price on Candel Therapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a research report on Friday. Nine equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Candel Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $18.29.

Read Our Latest Stock Report on CADL

Candel Therapeutics Price Performance

Candel Therapeutics stock opened at $5.81 on Monday. Candel Therapeutics has a 1 year low of $4.35 and a 1 year high of $14.00. The firm has a 50 day moving average price of $9.61 and a 200 day moving average price of $8.39. The company has a market cap of $444.58 million, a price-to-earnings ratio of -3.93 and a beta of -0.27. The company has a debt-to-equity ratio of 0.38, a quick ratio of 16.09 and a current ratio of 16.09.

Institutional Trading of Candel Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. AlphaCentric Advisors LLC lifted its position in Candel Therapeutics by 4.3% during the third quarter. AlphaCentric Advisors LLC now owns 38,259 shares of the company’s stock valued at $399,000 after buying an additional 1,576 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Candel Therapeutics by 19.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,962 shares of the company’s stock worth $152,000 after acquiring an additional 2,301 shares in the last quarter. Janney Montgomery Scott LLC raised its stake in shares of Candel Therapeutics by 12.6% in the 1st quarter. Janney Montgomery Scott LLC now owns 30,472 shares of the company’s stock valued at $149,000 after acquiring an additional 3,400 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Candel Therapeutics in the 3rd quarter valued at $41,000. Finally, Profund Advisors LLC lifted its holdings in shares of Candel Therapeutics by 16.1% during the 3rd quarter. Profund Advisors LLC now owns 33,301 shares of the company’s stock valued at $348,000 after acquiring an additional 4,624 shares in the last quarter. Institutional investors and hedge funds own 13.93% of the company’s stock.

Key Headlines Impacting Candel Therapeutics

These are some of the CADL headlines that stood out recently:

About Candel Therapeutics

(Get Free Report)

Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.

Recommended Stories

Earnings History and Estimates for Candel Therapeutics (NASDAQ:CADL)

Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.